MediPines, a renowned market leader, recognized by WHO in respiratory assessment and monitoring, has achieved yet another significant milestone. The World Health Organization (WHO) has recognized their flagship product, the MediPines AGM100® pulmonary gas exchange analyzer, as an innovative technology in their 2021 compendium titled \”WHO Compendium of Innovative Health Technologies for Low-Resource Settings.\” This recognition highlights the AGM100®\’s potential to make an immediate impact on COVID-19 and other general health outcomes, providing a valuable solution for low-resource settings.
Improving Respiratory Care in Low-Resource Settings:
The WHO\’s annual assessment report serves as a platform to create global awareness of technologies that can have a direct and positive impact on healthcare, particularly in resource-limited environments. Among the hundreds of technologies considered, the portable MediPines AGM100® recognized by WHO, was selected for its ability to detect changes in pulmonary gas exchange in diseases such as COPD, pneumonia, influenza, and ARDS caused by COVID-19. This recognition by the WHO reinforces the AGM100®\’s efficacy in delivering instant and accurate insights into patients\’ respiratory conditions.
Real-Time Monitoring Without Invasive Procedures:
One of the key features that sets the MediPines AGM100® apart is its ability to provide clinicians with a comprehensive view of patient blood oxygen and gas exchange levels at the bedside without the need for invasive procedures such as blood draws or needle sticks. This non-invasive approach enhances patient safety and care, particularly in low-resource settings where the risk of infections associated with invasive procedures is a concern. The real-time data provided by the AGM100® enables clinicians to promptly understand lung and blood conditions, facilitating timely interventions and improving patient outcomes.
Recognized by a Panel of International Experts:
The WHO compendium report is the result of a rigorous selection and evaluation process led by a panel of international experts. Influential physicians, biomedical engineers, and regulatory experts from 37 countries participated in assessing the potential of various medical technologies. Out of hundreds of contenders, only 24 technologies were chosen, and MediPines AGM100® was among the top 15 commercially available technologies highlighted. Additionally, this unique device has also been awarded by Medical Design Excellence Awards in the year 2021.
A Commitment to Combating Respiratory Diseases:
Steve Lee, CEO and co-inventor of the AGM100®, expressed his gratitude for the WHO\’s recognition and emphasized the product\’s significant contribution in assessing COVID-19 patients. MediPines remains dedicated to collaborating with healthcare professionals and policymakers in the fight against COVID-19 and other respiratory diseases. By providing physiology-based respiratory devices, the company aims to enhance clinical effectiveness and achieve better patient outcomes.
MediPines AGM 100 can help patients during following diseases:
- Idiopathic Pulmonary Fibrosis
- Pneumonia
- Long COVID
- COPD Exacerbation
- Coronary Artery Diseases
- Pulmonary Embolism
- Asbestosis
- Hypersensitivity Pneumonitis.
- Acute Respiratory Distress Syndrome
- Heart Failure
Conclusion:
The inclusion of MediPines AGM100® in the WHO Compendium of Innovative Health Technologies for Low-Resource Settings signifies a significant achievement for the company. The portable gas exchange analyzer has demonstrated its potential to revolutionize respiratory monitoring, especially in low-resource settings, by providing real-time, non-invasive insights into patients\’ lung and blood conditions. This recognition by the WHO further solidifies MediPines\’ commitment to advancing respiratory medicine and working towards better patient outcomes globally.
By
